eli lilly glp 1 market share Explore the Global GLP-1 Receptor Agonist — Analysis of Key Trends, Regional Growth, Top Players, and a 10-Year Forecast from 2026 to 2036 Eli Lilly Shows Why the

The only difference between the two is what theyre approved to treat (diabetes vs

The EMA and FDA imposed a respective label (52, 53)

The company is building additional fill-finish capacity in Brazil and China for local markets, expected online in 2027-2028

Literally have nothing in my system, so for me to even take tirzepatide is a huge decision." Tirzepatide is often marketed under the name Mounjaro or Zepbound, though Bunnie did not specify if she was using either brand

The access-to-care problem is usually what we are actually solving

[Accessed on 11 June 2026] Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (2025)